Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Acrivon launches internal CLIA-certified lab

Acrivon Therapeutics (NASDAQ: ACRV) has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in...

February 18, 2026

Developments

Lipocine Completes Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression

Lipocine (NASDAQ: LPCN) has announced that the last patient has completed the final study visit in the Phase 3 trial of its oral brexanolon, LPCN 1154, for the treatment of postpartum depression (PPD). According to...

February 18, 2026

Developments

IP Australia grants Klotho 18 claims for s-KL

Klotho Neurosciences (NASDAQ: KLTO) has announced that IP Australia has accepted 18 claims within its patent application covering the composition and use of its human secreted Klotho protein, s-KL isoform. The patent...

February 18, 2026

Developments

Bioxytran reports positive Phase 2 data for ProLectin-M

Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with...

February 13, 2026

Developments

FDA clears Precision’s IND for PBGENE-DMD

Precision BioSciences (NASDAQ: DTIL) has announced that the FDA has granted a Study May Proceed notification, allowing initiation of clinical trial site activation for the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD in...

February 13, 2026

Executive Moves

ROTH expands healthcare team across banking, sales, research

Investment bank ROTH Capital Partners LLC has further expanded its healthcare platform across investment banking, institutional sales, and equity research with the addition of Jack Terranova, Noah Huehnergarth, and Max...

February 13, 2026

Developments

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy and AI...

February 12, 2026

Developments

BioSyent to acquire Oral Science

BioSyent (TSXV: RX) has entered into a Share Purchase Agreement to acquire closely held Oral Science, a Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard...

February 10, 2026

Developments

PreveCeutical files patent for delivery of CNS-active agents

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF) has filed an international patent application for the delivery of CNS-active therapeutic agents covering methods and formulations aimed at addressing treatment challenges...

February 9, 2026

Executive Moves

Rita Johnson-Greene joins Ocugen as CFO

Ocugen (NASDAQ: OCGN) has appointed Rita Johnson-Greene as chief financial officer (CFO). Ms. Johnson-Greene brings more than 20 years of healthcare experience to the role. Most recently, she served as chief operating...

February 9, 2026

Developments

Exicure reports publication highlighting Phase 2 burixafor data showing rapid stem cell mobilization

Exicure (NASDAQ: XCUR) announced that Annals of Hematology has published results from a Phase 2 clinical study demonstrating rapid stem cell mobilization with burixafor (GPC-100/TG-0054)—a highly selective CXCR4...

February 6, 2026

Developments

Cognition lengthens Zervimesine program in DLB

Cognition Therapeutics (NASDAQ: CGTX) has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB) from the original 12 months to include several more months of treatment. According...

February 6, 2026

Subscribe